Literature DB >> 11157490

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.

T L Holyoake1, X Jiang, H G Jorgensen, S Graham, M J Alcorn, C Laird, A C Eaves, C J Eaves.   

Abstract

It was previously shown that patients with chronic myeloid leukemia (CML) have a rare but consistently detectable population of quiescent (G0) leukemic (Philadelphia chromosome-positive and BCR-ABL-positive [BCR-ABL+]) CD34+ cells. In the study described here, most such cells expressed a primitive phenotype (CD38-, CD45RA-, CD71-, and HLA-DR(lo)) and cultures of these cells containing growth factors produced ultimately larger, but initially more slowly growing clones than do cultures of initially cycling CD34+ leukemic cells. Initially quiescent leukemic cells expressing BCR-ABL proliferated in single-cell cultures in the absence of added growth factors, thereby demonstrating their ability to spontaneously exit G0 and enter a continuously cycling state. Interestingly, on isolation, few of these quiescent BCR-ABL+ cells contained either interleukin-3 (IL-3) or granulocyte colony-stimulating factor (G-CSF) transcripts, whereas both were present in most cycling BCR-ABL+ CD34+ cells. However, after 4 days of culture in the absence of added growth factors and in association with their entry into the cell cycle (as indicated by up-regulation of Ki-67 and cdc25 transcripts), IL-3 transcripts became detectable. These findings show that entry of leukemic (BCR-ABL-expressing) progenitors into a quiescent (G0) state in vivo is highest among the most primitive leukemic cell populations, associated with a down-regulation of IL-3 and G-CSF gene expression, and spontaneously reversible in association with up-regulation of IL-3 expression. These results highlight the potential physiologic relevance of quiescent CML progenitors, even in treated patients, in whom these cells would be predicted to have a proliferative advantage over their quiescent normal counterparts when cytokine concentrations are low.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157490     DOI: 10.1182/blood.v97.3.720

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

2.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

3.  Extinction models for cancer stem cell therapy.

Authors:  Mary Sehl; Hua Zhou; Janet S Sinsheimer; Kenneth L Lange
Journal:  Math Biosci       Date:  2011-10-06       Impact factor: 2.144

4.  Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia.

Authors:  Donald Metcalf; Aleksandar Dakic; Sandra Mifsud; Ladina Di Rago; Li Wu; Stephen Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

5.  Use of oncolytic viruses for the eradication of drug-resistant cancer cells.

Authors:  Dominik Wodarz
Journal:  J R Soc Interface       Date:  2009-02-06       Impact factor: 4.118

6.  Isolation and therapeutic potential of human haemopoietic stem cells.

Authors:  Andrew D Clark; Heather G Jørgensen; Joanne Mountford; Tessa L Holyoake
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

7.  Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.

Authors:  S Halbach; M Köhler; F M Uhl; J Huber; R Zeiser; S Koschmieder; K Aumann; T Brummer
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

8.  Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

Authors:  Xiaoyan Jiang; Donna Forrest; Franck Nicolini; Ali Turhan; Joelle Guilhot; Calvin Yip; Tessa Holyoake; Heather Jorgensen; Karen Lambie; Kyi Min Saw; Emily Pang; Ranko Vukovic; Paeta Lehn; Ashley Ringrose; Miao Yu; Ryan R Brinkman; Clay Smith; Allen Eaves; Connie Eaves
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

9.  Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Authors:  Heiko Konig; Mhairi Copland; Su Chu; Richard Jove; Tessa L Holyoake; Ravi Bhatia
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

10.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.